Sodium risedronate

Bezeichnung:Sodium risedronate

CAS-Nr115436-72-1

Englisch Name:Sodium risedronate

CBNumberCB1414620

SummenformelC7H12NNaO7P2

Molgewicht307.11

MOL-Datei115436-72-1.mol

Sodium risedronate physikalisch-chemischer Eigenschaften

Schmelzpunkt	252-262°C
storage temp.	room temp
Löslichkeit	H2O: soluble5mg/mL, clear (warmed)
Aggregatzustand	powder
Farbe	white to beige
Wasserlöslichkeit	Soluble to 10 mM in water
BCS Class	3
Stabilität	Hygroscopic
CAS Datenbank	115436-72-1(CAS DataBase Reference)

Sicherheit

R-Sätze:	62-64
S-Sätze:	20-22-36/37
WGK Germany	3
RTECS-Nr.	SZ8567500
HS Code	29333990

Gefahreninformationscode (GHS)

Sodium risedronate Chemische Eigenschaften,Einsatz,Produktion Methoden

Beschreibung
Risedronate sodium was launched as Actonel in the US for treatment of Paget's disease. Risedronic acid is readily obtained by condensation of 2-(3- pyridyl)acetic acid with phosphorous acid in presence of phosphorus oxychloride. Risedronate sodium is an orally active bisphosphonate of third generation, showing more potent bone antiresorptive properties than most of prior bisphosphonates like etidronate which has been used for the same indication since 1978. The biological mechanism by which Risedronate, and generally bisphosphonates, act is not quite clear presently ; recent advances have suggested that aminobisphosphonates interfere with the HMG-CoA pathway and inhibit protein prenylation, causing apoptosis of osteoclasts and macrophages. These apoptotic effects are correlated to the anti-resorptive properties of this class of compounds. In a 2 month clinical trial involving patients with Paget's desease, 30 mg risedronate daily achieved an appreciable reduction of serum alkaline phosphatase levels, an indicator of bone stabilization, in 77% of patients, compared with 11% on etidronate at 400 mg daily for 6 months. Risedronate is also in development for the treatment and prevention of various bone diseases, particularly post-menopausal and corticosteroid-induced osteoporosis.
Chemische Eigenschaften
Fine White to Off-White Crystalline Powder
Originator
Procter Gamble (US)
Verwenden
Osteoporosis
Verwenden
antibacterial
Verwenden
Risedronic Acid is a pyridinyl biphosphonate bone resorption inhibitor.
Definition
ChEBI: Risedronate sodium is a 1,1-bis(phosphonic acid).
Trademarks
Actonel (Procter & Gamble).
Hazard
Human systemic effects.
Biologische Aktivität
Orally active biphosphonate that inhibits farnesyl diphosphate (FPP) synthase. Exhibits antiproliferative and proapoptotic activity in numerous tumor cell lines and inhibits osteoclast-mediated bone reabsorption in vivo .
Biochem/physiol Actions
Risedronate sodium is a bisphosphonate bone resorption inhibitor. It has an affinity for hydroxyapatite crystals in bone and acts as an antiresorptive agent and is an inhibitor of farnesyl diphosphate (FPP) synthase, which results in downstream inhibition of osteoclast activity and reduced bone resorption and turnover. Risedronate sodium has been used to treat postmenopausal osteoporosis and Paget′s disease.
Clinical Use
Bisphosphonate:
Treatment and prevention of osteoporosis (including corticosteroid induced)
Paget’s disease
Arzneimittelwechselwirkung
Potentially hazardous interactions with other drugs
Calcium-containing substances: avoid for 2 hours before and after administration.
Stoffwechsel
The mean bioavailability of risedronate is 0.63% in the fasting state, and there is no evidence of systemic metabolism of risedronate sodium.
About half of the absorbed portion is excreted in the urine within 24 hours; the remainder is sequestered to bone for a prolonged period. Unabsorbed drug is eliminated unchanged in the faeces.
Lager
Store at RT

Sodium risedronate Anbieter Lieferant Produzent Hersteller Vertrieb Händler.

115436-72-1, Sodium risedronate Verwandte Suche:

Send Inquriy